Get the Stockscreener App
2.775
2.90%
-0.085
Metagenomi Inc stock is traded at $2.775, with a volume of 81,947.
It is down -2.90% in the last 24 hours and up +49.30% over the past month.
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
See More
Previous Close:
$2.86
Open:
$2.96
24h Volume:
81,947
Relative Volume:
0.14
Market Cap:
$104.23M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+3.23%
1M Performance:
+49.30%
6M Performance:
+87.64%
1Y Performance:
+41.68%
1-Day Range:
$2.77
$2.98
1-Week Range:
$2.71
$3.28
52-Week Range:
$1.23
$4.92
Metagenomi Inc Stock (MGX) Company Profile
Name
Metagenomi Inc
Sector
Industry
Phone
(510) 871-4880
Address
5959 HORTON STREET, EMERYVILLE
Compare MGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Inc
|
2.777 | 107.34M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.58 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.01 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
544.91 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.67 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
325.17 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Metagenomi Inc Stock (MGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Initiated | H.C. Wainwright | Buy |
| May-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-05-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-24 | Initiated | Chardan Capital Markets | Buy |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Mar-05-24 | Initiated | Jefferies | Buy |
| Mar-05-24 | Initiated | TD Cowen | Outperform |
| Mar-05-24 | Initiated | Wells Fargo | Overweight |
View All
Metagenomi Inc Stock (MGX) Latest News
Will Metagenomi Inc. stock go up soon2025 Year in Review & High Accuracy Trade Alerts - newser.com
Will Metagenomi Inc. stock see insider buyingBull Run & Safe Capital Growth Plans - newser.com
Metagenomi's (MGX) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
What candlestick patterns are forming on Metagenomi Inc.2025 Risk Factors & AI Forecasted Entry and Exit Points - newser.com
What recovery options are there for Metagenomi Inc.Market Rally & Long-Term Growth Stock Strategies - newser.com
Measuring Metagenomi Inc.’s beta against major indicesTrade Analysis Summary & Weekly Market Pulse Updates - newser.com
How Metagenomi Inc. stock performs in rate cut cyclesWeekly Trade Analysis & AI Enhanced Market Trend Forecasts - newser.com
Why Metagenomi Inc. stock could outperform in 20252025 Trading Volume Trends & Expert Approved Momentum Trade Ideas - newser.com
Custom watchlist performance reports with Metagenomi Inc.Quarterly Earnings Report & Safe Capital Growth Stock Tips - newser.com
Detecting support and resistance levels for Metagenomi Inc.July 2025 Weekly Recap & Weekly High Potential Alerts - newser.com
Best data tools to analyze Metagenomi Inc. stockEarnings Recap Summary & Community Supported Trade Ideas - newser.com
Why Metagenomi Inc. stock could be next big winner2025 Volume Leaders & Community Verified Watchlist Alerts - newser.com
Metagenomi (NASDAQ:MGX) versus SCYNEXIS (NASDAQ:SCYX) Head-To-Head Analysis - Defense World
What technical signals suggest for Metagenomi Inc. stockJuly 2025 Trade Ideas & Daily Risk Controlled Trade Plans - newser.com
Can you recover from losses in Metagenomi Inc.Market Movement Recap & Accurate Entry and Exit Point Alerts - newser.com
Metagenomi, Inc. Enters into A Non-Exclusive License Agreement with Acuitas Therapeutics, Inc - MarketScreener
Goldman Sachs Group Inc. Trims Stock Position in Metagenomi, Inc. $MGX - Defense World
Metagenomi Inc Stock (MGX) Financials Data
There is no financial data for Metagenomi Inc (MGX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.20%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):